A validated UPLC–MS/MS method for flibanserin in plasma and its pharmacokinetic interaction with bosentan in rats-Reference-Cited by-同舟云学术

A validated UPLC–MS/MS method for flibanserin in plasma and its pharmacokinetic interaction with bosentan in rats

Published:2018-07 Issue:14 Volume:10 Page:1087-1097
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Iqbal Muzaffar¹²,Ezzeldin Essam¹²,Rezk Naser L³,Bajrai Amal A⁴,Al-Rashood Khalid A¹

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box No 2457 Riyadh, Saudi Arabia

2. Bioavailability Laboratory, College of Pharmacy, King Saud University, PO Box No 2457 Riyadh, Saudi Arabia

3. Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Medina, Saudi Arabia

4. Consultant, Obesity Centre, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Abstract

Aim: The purpose of this study was development, validation and application of ultra-performance liquid chromatography (UPLC)–ESI–MS/MS method for quantitation of flibanserin in plasma samples.Method & results: After extraction of analyte from plasma by diethyl ether, separation was performed on UPLC C18 column using mobile phase composition of 10 mM ammonium formate-acetonitrile (30:70, v/v) by isocratic elution of 0.3 ml/min. The multiple reaction monitoring transitions of m/z 391.13 → 161.04 and 384.20 → 253.06 were used for detection of analyte and internal standard (quetiapine), respectively. The calibration curves were linear (r ≥ 0.995) between 0.22 and 555 ng/ml concentration and all validation results were within the acceptable range as per US FDA guidelines. Conclusion: The assay procedure was fully validated and successfully applied in pharmacokinetic interaction study of flibanserin with bosentan in rats.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio-2018-0065

Reference21 articles.

1. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study

2. FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder

3. US prescribing information of Addyi (flibanserin) tablets, for oral use: Sprout Pharmaceuticals, Inc (2015). www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zirconium-based hydrophobic-MOFs as innovative electrode modifiers for flibanserin determination: Exploring the electrooxidation mechanism using a comprehensive spectroelectrochemical study;Microchimica Acta;2024-04-03

2. Development of a New, Fully Validated LC-MS/MS Method for the Analysis of Flibanserin in Pharmaceutical Preparations and Comparison of the Chromatographic Performance with Six Stationary Phase Types;Current Analytical Chemistry;2023-08

3. A Different Perspective on the Characterization of a New Degradation Product of Flibanserin With HPLC–DAD–ESI-IT-TOF-MSn and Its Pharmaceutical Formulation Analysis With Inter-Laboratory Comparison;Journal of AOAC International;2023-06-22

4. Emphasis on the incorporation of Tropaeolin OO dye and silver nanoparticles for voltammetric estimation of flibanserin in bulk form, tablets and human plasma;Talanta;2022-08

5. Development and validation of a novel evaporation setup-assisted TLC method with fluorescence detection for determination of flibanserin in pharmaceutical and biological samples;Journal of Chromatography B;2022-04